HU231333B1 - Spirokromán származékok - Google Patents

Spirokromán származékok Download PDF

Info

Publication number
HU231333B1
HU231333B1 HUP1800248A HUP1800248A HU231333B1 HU 231333 B1 HU231333 B1 HU 231333B1 HU P1800248 A HUP1800248 A HU P1800248A HU P1800248 A HUP1800248 A HU P1800248A HU 231333 B1 HU231333 B1 HU 231333B1
Authority
HU
Hungary
Prior art keywords
disorders
disorder
methyl
alkyl
disease
Prior art date
Application number
HUP1800248A
Other languages
English (en)
Hungarian (hu)
Inventor
Éles János 30% dr.
Molnár Katalin 20% Dudásné
Ledneczki István 10% dr.
Tapolcsányi Pál 10% dr.
Horváth Anita 10% dr.
Némethy Zsolt 10% dr.
Lévay György István 10% dr.
Original Assignee
Richter Gedeon Nyrt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Richter Gedeon Nyrt filed Critical Richter Gedeon Nyrt
Priority to HUP1800248A priority Critical patent/HU231333B1/hu
Priority to TW108122548A priority patent/TWI821321B/zh
Priority to AU2019300514A priority patent/AU2019300514B2/en
Priority to HUE19744868A priority patent/HUE064417T2/hu
Priority to PE2021000053A priority patent/PE20211809A1/es
Priority to EA202190245A priority patent/EA202190245A1/ru
Priority to GEAP202315557A priority patent/GEAP202315557A/en
Priority to ARP190101991A priority patent/AR115782A1/es
Priority to KR1020217004264A priority patent/KR20210033002A/ko
Priority to BR112020026996-4A priority patent/BR112020026996A2/pt
Priority to SG11202012594RA priority patent/SG11202012594RA/en
Priority to MX2021000460A priority patent/MX2021000460A/es
Priority to CU2020000108A priority patent/CU24680B1/es
Priority to CN201980046665.7A priority patent/CN112823157B/zh
Priority to ES19744868T priority patent/ES2964617T3/es
Priority to US17/259,972 priority patent/US20210330650A1/en
Priority to MYPI2020006684A priority patent/MY206779A/en
Priority to GEAP201915557A priority patent/GEP20237534B/en
Priority to CA3104258A priority patent/CA3104258A1/en
Priority to EP19744868.1A priority patent/EP3820869B1/en
Priority to IL279938A priority patent/IL279938B2/en
Priority to JP2021500532A priority patent/JP7487167B2/ja
Priority to PCT/IB2019/055948 priority patent/WO2020012422A1/en
Publication of HUP1800248A2 publication Critical patent/HUP1800248A2/hu
Priority to PH12020552183A priority patent/PH12020552183A1/en
Priority to CL2021000080A priority patent/CL2021000080A1/es
Priority to CONC2021/0001216A priority patent/CO2021001216A2/es
Publication of HU231333B1 publication Critical patent/HU231333B1/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
HUP1800248A 2018-07-13 2018-07-13 Spirokromán származékok HU231333B1 (hu)

Priority Applications (26)

Application Number Priority Date Filing Date Title
HUP1800248A HU231333B1 (hu) 2018-07-13 2018-07-13 Spirokromán származékok
TW108122548A TWI821321B (zh) 2018-07-13 2019-06-27 唍衍生物
CN201980046665.7A CN112823157B (zh) 2018-07-13 2019-07-12 螺色满衍生物
US17/259,972 US20210330650A1 (en) 2018-07-13 2019-07-12 Spirochromane derivatives
PE2021000053A PE20211809A1 (es) 2018-07-13 2019-07-12 Derivados de espirocromano
EA202190245A EA202190245A1 (ru) 2018-07-13 2019-07-12 Производные спирохромана
GEAP202315557A GEAP202315557A (en) 2018-07-13 2019-07-12 Spirochromane derivatives
ARP190101991A AR115782A1 (es) 2018-07-13 2019-07-12 DERIVADOS DE ESPIROCROMANO, UN MÉTODO PARA SU PREPARACIÓN, INTERMEDIARIOS PARA SU SÍNTESIS, COMPOSICIÓN Y COMBINACIÓN FARMACÉUTICA QUE LOS COMPRENDEN Y EL USO DE LOS MISMOS EN EL TRATAMIENTO DE ENFERMEDADES ASOCIADAS AL RECEPTOR NICOTÍNICO DE ACETILCOLINA a7
KR1020217004264A KR20210033002A (ko) 2018-07-13 2019-07-12 스피로크로만 유도체
BR112020026996-4A BR112020026996A2 (pt) 2018-07-13 2019-07-12 Composto, uso de composto, método para o tratamento ou prevenção de um transtorno associado à atividade de receptor nicotínico a7 de acetilcolina, composição farmacêutica, combinação, e, processo para fabricação de compostos
SG11202012594RA SG11202012594RA (en) 2018-07-13 2019-07-12 Spirochromane derivatives
MX2021000460A MX2021000460A (es) 2018-07-13 2019-07-12 Derivados de espirocromano.
CU2020000108A CU24680B1 (es) 2018-07-13 2019-07-12 Derivados de espirocromano como moduladores del receptor de acetilcolina nicotínica alfa7
AU2019300514A AU2019300514B2 (en) 2018-07-13 2019-07-12 Spirochromane derivatives
ES19744868T ES2964617T3 (es) 2018-07-13 2019-07-12 Derivados del espirocromano
HUE19744868A HUE064417T2 (hu) 2018-07-13 2019-07-12 Spirokromán származékok
MYPI2020006684A MY206779A (en) 2018-07-13 2019-07-12 Spirochromane derivatives
GEAP201915557A GEP20237534B (en) 2018-07-13 2019-07-12 Spirochromane derivatives
CA3104258A CA3104258A1 (en) 2018-07-13 2019-07-12 Spirochromane derivatives
EP19744868.1A EP3820869B1 (en) 2018-07-13 2019-07-12 Spirochromane derivatives
IL279938A IL279938B2 (en) 2018-07-13 2019-07-12 History of Spirochroman
JP2021500532A JP7487167B2 (ja) 2018-07-13 2019-07-12 スピロクロマン誘導体
PCT/IB2019/055948 WO2020012422A1 (en) 2018-07-13 2019-07-12 Spirochromane derivatives
PH12020552183A PH12020552183A1 (en) 2018-07-13 2020-12-16 Spirochromane derivatives
CL2021000080A CL2021000080A1 (es) 2018-07-13 2021-01-12 Derivados de espirocromano
CONC2021/0001216A CO2021001216A2 (es) 2018-07-13 2021-02-03 Derivados de espirocromano

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
HUP1800248A HU231333B1 (hu) 2018-07-13 2018-07-13 Spirokromán származékok

Publications (2)

Publication Number Publication Date
HUP1800248A2 HUP1800248A2 (en) 2020-01-28
HU231333B1 true HU231333B1 (hu) 2023-01-28

Family

ID=89992725

Family Applications (2)

Application Number Title Priority Date Filing Date
HUP1800248A HU231333B1 (hu) 2018-07-13 2018-07-13 Spirokromán származékok
HUE19744868A HUE064417T2 (hu) 2018-07-13 2019-07-12 Spirokromán származékok

Family Applications After (1)

Application Number Title Priority Date Filing Date
HUE19744868A HUE064417T2 (hu) 2018-07-13 2019-07-12 Spirokromán származékok

Country Status (24)

Country Link
US (1) US20210330650A1 (https=)
EP (1) EP3820869B1 (https=)
JP (1) JP7487167B2 (https=)
KR (1) KR20210033002A (https=)
CN (1) CN112823157B (https=)
AR (1) AR115782A1 (https=)
AU (1) AU2019300514B2 (https=)
BR (1) BR112020026996A2 (https=)
CA (1) CA3104258A1 (https=)
CL (1) CL2021000080A1 (https=)
CO (1) CO2021001216A2 (https=)
CU (1) CU24680B1 (https=)
EA (1) EA202190245A1 (https=)
ES (1) ES2964617T3 (https=)
GE (2) GEAP202315557A (https=)
HU (2) HU231333B1 (https=)
IL (1) IL279938B2 (https=)
MX (1) MX2021000460A (https=)
MY (1) MY206779A (https=)
PE (1) PE20211809A1 (https=)
PH (1) PH12020552183A1 (https=)
SG (1) SG11202012594RA (https=)
TW (1) TWI821321B (https=)
WO (1) WO2020012422A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU231414B1 (hu) 2018-07-13 2023-08-28 Richter Gedeon Nyrt. Tiadiazin származékok
TWI901650B (zh) 2020-03-26 2025-10-21 匈牙利商羅特格登公司 啶及吡啶并〔３，４－ｃ〕嗒衍生物
CN115403579A (zh) * 2021-05-27 2022-11-29 上海拓界生物医药科技有限公司 一种新的螺环衍生物及其用途
HU231691B1 (hu) 2021-09-29 2025-10-28 Richter Gedeon Nyrt GABAA ALFA5 receptor modulátor hatású biciklusos aminszármazékok
WO2025175249A1 (en) 2024-02-14 2025-08-21 Olema Pharmaceuticals, Inc. Estrogen receptor modulators and uses thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006016548A1 (ja) 2004-08-09 2006-02-16 Eisai R & D Management Co., Ltd. ヘテロ環化合物を含有する新規な抗マラリア剤
NZ566036A (en) 2005-09-13 2010-06-25 Janssen Pharmaceutica Nv 2-Aniline-4-aryl substituted thiazole derivatives that modulate the alpha7 nicotinic receptor
CN101490056A (zh) * 2006-05-17 2009-07-22 阿斯利康(瑞典)有限公司 烟碱乙酰胆碱受体的配体101
TW200813067A (en) * 2006-05-17 2008-03-16 Astrazeneca Ab Nicotinic acetylcholine receptor ligands
US20100298314A1 (en) 2006-12-20 2010-11-25 Schering Corporation Novel jnk inhibitors
MX2010003156A (es) 2007-10-04 2010-04-01 Hoffmann La Roche Derivados de aril amida substituida con tetrazol y usos de los mismos.
MX2010003155A (es) 2007-10-04 2010-04-01 Hoffmann La Roche Derivados de ciclopropil aril amida y uso de los mismos.
KR20100124272A (ko) 2008-02-07 2010-11-26 아보트 러보러터리즈 양성 알로스테릭 조절제로서의 아미드 유도체 및 이의 사용방법
AR070936A1 (es) 2008-03-19 2010-05-12 Janssen Pharmaceutica Nv 1,2,4 -triazoles trisustituidos
EP2110377A1 (en) * 2008-04-15 2009-10-21 DAC S.r.l. Spirocyclic derivatives as histone deacetylase inhibitors
WO2009127678A1 (en) * 2008-04-17 2009-10-22 Glaxo Group Limited Indoles as modulators of nicotinic acetylcholin receptor subtype alpha-71
JP5486591B2 (ja) 2008-05-09 2014-05-07 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ アセチルコリン受容体モジュレーターとしての三置換ピラゾール
CA2725940A1 (en) 2008-05-30 2009-12-23 Merck Sharp & Dohme Corp. Novel substituted azabenzoxazoles
EP3795573B1 (en) 2009-12-31 2022-07-06 Hutchison Medipharma Limited Certain triazolopyrazines, compositions thereof and methods of use therefor
WO2012042915A1 (en) 2010-10-01 2012-04-05 Raqualia Pharma Inc. Sulfamoyl benzoic acid heterobicyclic derivatives as trpm8 antagonists
US9617210B2 (en) * 2013-03-13 2017-04-11 Lupin Limited Pyrrole derivatives as alpha 7 NACHR modulators
AR107928A1 (es) 2016-03-22 2018-06-28 Merck Sharp & Dohme Moduladores alostéricos de receptores de acetilcolina nicotínicos
US10870630B2 (en) 2016-11-01 2020-12-22 Merck Sharp & Dohme Corp. Substituted bicyclic heteroaryl allosteric modulators of nicotinic acetylcholine receptors
WO2018112204A1 (en) * 2016-12-14 2018-06-21 Cephalon, Inc. Spiropiperidine derivatives

Also Published As

Publication number Publication date
KR20210033002A (ko) 2021-03-25
AU2019300514A1 (en) 2021-02-11
CU24680B1 (es) 2023-10-06
HUP1800248A2 (en) 2020-01-28
GEP20237534B (en) 2023-09-11
CO2021001216A2 (es) 2021-02-26
JP2021531260A (ja) 2021-11-18
AR115782A1 (es) 2021-02-24
AU2019300514B2 (en) 2023-02-02
GEAP202315557A (en) 2023-05-10
CN112823157A (zh) 2021-05-18
ES2964617T3 (es) 2024-04-08
EP3820869A1 (en) 2021-05-19
IL279938A (en) 2021-03-01
MX2021000460A (es) 2021-06-23
US20210330650A1 (en) 2021-10-28
PH12020552183A1 (en) 2021-06-21
IL279938B1 (en) 2024-09-01
SG11202012594RA (en) 2021-02-25
WO2020012422A1 (en) 2020-01-16
CL2021000080A1 (es) 2021-10-29
EA202190245A1 (ru) 2021-04-20
EP3820869B1 (en) 2023-08-30
PE20211809A1 (es) 2021-09-14
CU20200108A7 (es) 2021-07-02
IL279938B2 (en) 2025-01-01
TWI821321B (zh) 2023-11-11
HUE064417T2 (hu) 2024-03-28
BR112020026996A2 (pt) 2021-04-06
TW202035399A (zh) 2020-10-01
MY206779A (en) 2025-01-07
CA3104258A1 (en) 2020-01-16
CN112823157B (zh) 2024-08-09
JP7487167B2 (ja) 2024-05-20

Similar Documents

Publication Publication Date Title
EP3820869B1 (en) Spirochromane derivatives
TWI829676B (zh) 噁二唑暫時受體電位通道抑制劑
CA3065077C (en) Novel biphenyl compound or salt thereof
CN109996792A (zh) 具有在治疗cns疾病和疼痛中作为毒蕈碱性m1和/或m4受体的调节剂的活性的杂环化合物
US20250064823A1 (en) Thiadiazine derivatives
WO2005051949A1 (ja) 新規縮合イミダゾール誘導体
CN112805063B (zh) 作为gabaa a5受体调节剂的双环衍生物
TW202017904A (zh) 經取代之（吖）吲哚衍生物
HK40044485B (en) Spirochromane derivatives
HK40044485A (en) Spirochromane derivatives
RS53032B (sr) Derivati dihidro-oksazolobenzodiazepinona, postupci za njihovu proizvodnju i farmaceutske smeše koje sadrže ova jedinjenja
OA20784A (en) Spirochromane derivatives
EA043926B1 (ru) Производные спирохромана
EP3227293A1 (en) 6.7-cyclicmorphinan derivatives and use thereof
OA19571A (en) Triazolobenzazepines as vasopressin V1a receptor antagonists.